-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 20, CDE's official website showed that Chia Tai Tianqing's Class 1 new drug TQ-B3139 was declared for listi.
From: CDE official website
TQ-B3139 (CT-1139) is a c-Met/ALK/ROS multi-target tyrosine kinase inhibitor jointly developed by Chia Tai Tianqing and Shouyao Holdi.
According to theInsight database , the fastest-growing Phase III clinical trial of TQ-B3139was launched in 2019, aiming to compare the efficacy and safety of the drug with crizotinib in the treatment of ALK-positive advanced NSCLC; while the Phase II clinical trial aimed at two Indications: ALK-positive advanced NSCLC after crizotinib resistance, and MET gene abnormal NSC.
In addition to lung cancer, TQ-B3139 has two different cancer indications approved for clinical use, namely diffuse large B-cell lymphoma and neuroblastoma, but clinical trials have not yet start.
Progress of clinical trials of TQ-B3139 in various indications
From: Insight database(http://.
At the 2020 ASCO conference, Chia Tai Tianqing published a phase 1 clinical data of TQ-B3139 (NCT03099330, abstract number: 958
The Insight databaseshows that Tianqing has more than one drug on the ALK targ.
Chia Tai Tianqing ALK target innovative drug
From: Insight database(http://.
According tothe Insight database, the Phase 2 clinical trial of TQ-B3101targets ROS1 fusion-positive advanced NSCLC ( CTR20191078 .
From: 2021 ELCC
However, the domestic competition for ALK targets is very fierce, and 6 new drugs have been approved for marketing: the first-generation ALK inhibitor crizotinib, the second-generation ALK inhibitors ceritinib, alectinib, ensatinib, BUG Lorlatinib, a third-generation ALK inhibit.
ALK target domestic competition pattern
From: Insight database(http://.
In recent years, Chia Tai Tianqing's innovative research and development has entered the fast la.
From: Insight database(http://.
Judging from the current progress of innovative drug projects in the pipeline, in addition to TQ-B3139 declared today, Tianqing has 3 new drugs in Phase III clinical trials , namely CDK4/6 inhibitor TQB3616, third-generation EGFR inhibitor FHND9041 and PD- L1 monoclonal antibody TQB2450; another 8 new drugs are in Phase II clinical trials, and 42 new drugs are in Phase I clinical tria.
